Epidermal growth factor receptor is expressed and active in a subset of acute myeloid leukemia

The epidermal growth factor receptor (EGFR) inhibitor erlotinib has been shown to induce complete remission of acute myeloid leukemia (AML) in two patients with concurrent lung cancer and raised attention for a role of EGFR in AML whereas a recent phase II clinical study with gefitinib in AML demons...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahmud, Hasan, Kornblau, Steven M., ter Elst, Arja, Scherpen, Frank J. G., Qiu, Yi Hua, Coombes, Kevin R., de Bont, Eveline S. J. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4971659/
https://www.ncbi.nlm.nih.gov/pubmed/27488458
http://dx.doi.org/10.1186/s13045-016-0294-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4971659/
https://www.ncbi.nlm.nih.gov/pubmed/27488458
http://dx.doi.org/10.1186/s13045-016-0294-x

Ejemplares similares